Chinese patent expiration dates draw closer for Novo Nordisk

After a string of years characterized by growth for Novo Nordisk, in 2022, the Danish pharmaceutical firm has been hit by a large pricing reform in China. More challenges loom on the horizon in the country, which is the firm’s second-biggest market, as reported by Danish media Finans.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk remains coy over Wegovy blockbuster potential
For subscribers